Deal: Melbourne-based global developer and manufacturer of analytical and life sciences instruments and devices Trajan has successfully completed its initial public offering and ASX listing. Proceeds from the IPO will be used to execute on the company’s “exciting global growth initiatives”.

Value: The IPO raised $90 million at an offer price of $1.70 per share. 

Area: Capital markets.

Key players: The cross-jurisdictional team was led by partner Chris Mitchell with support from senior associate Chanel Mercurio, and solicitors Simon Rimmelzwaan and Davina Khoo. Mr Mitchell and the Australian team were supported by colleagues from the US, UK, Japan, Singapore, Canada, France, Switzerland, Germany and Denmark.

Deal significance: Mr Mitchell said it was an “absolute pleasure” to assist Trajan in its listing.

“A big congratulations to founders, Stephen and Angela Tomisich, who have created an incredible company with global infrastructure, unique technologies and, importantly, a dedicated team that is truly focused on science that benefits people and having an impact on human wellbeing,” he said.

“We look forward to continuing to support the Trajan team as they implement their global growth initiatives.”

VIEW ALL

Trajan chief executive and co-founder Stephen Tomisich added: “DLA played a critical role in our successful IPO. They lead the program with discipline and intensity ensuring on time delivery of the vital milestones along the way.

“The IPO process went very smoothly which was testament to the collaborative approach and hard work from everyone involved.”